Industry: Consumer Goods

OFF LIST - 2424 consecutive market days: OFF LIST as of 10/18/2006 Through 11/14/2016

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Current Quote*
Last: $8.323
Change: 0.403
Book: $1.476
Volume: 41,599

As Of: 08/22 13:14 ET
*Quotes delayed by 20min.

Graphs for HOOK

3 Month Graph

6 Month Graph

1 Year Graph